Skip to content
Peptide research

Dihexa

Also known as N-Hexanoic-Tyr-Ile-(6)-Aminohexanoic Amide · PNB-0408
Category
Brain & Cognition
Administration routes
Oral
Regulatory status
Not FDA-approved

What it is

A synthetic, orally active peptide marketed for memory and cognition, said to amplify HGF signaling and spur new synapse formation. The case rests entirely on rodent studies, with only speculative results in an Alzheimer's mouse model and no human safety data. Its core mechanism, HGF/c-Met, is a known cancer-promoting pathway, and the 2014 paper establishing it was retracted in 2025. It is an unregulated research chemical, not an approved drug in the US.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Potent synaptogenesis promotion

    Low

    Cultured rat neurons grew more dendritic spines at picomolar doses in one 2013 study.

  • Rescue of scopolamine-induced cognitive deficits

    Low

    Oral dosing reversed a chemically induced memory deficit in rats, one lab, no human data.

  • Cognitive restoration in Alzheimer's mouse model

    Speculative

    A 2021 APP/PS1 mouse study reported improved spatial learning; no human cognitive benefit is established.

Evidence limits

Evidence Level
Preclinical

All published evidence for dihexa itself comes from in vitro cell culture studies and rodent models. No human clinical trials of dihexa have been conducted or published. The pro-drug fosgonimeton has undergone Phase 2/3 human trials for Alzheimer's disease (LIFT-AD study), which did not meet primary endpoints but showed directional biomarker improvements. The foundational 2014 mechanism paper was retracted in April 2025, adding uncertainty to some claims.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active cancer

    High

    Amplifies HGF/c-Met signaling, which is a known oncogenic pathway in many cancers.

General cautions

  • Pregnancy

    Absolute

    HGF pathway is critical for embryonic development. Modulation could be teratogenic.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • HGF/c-Met signaling is a well-established oncogenic pathway

    High
  • Dose-dependent hepatotoxicity reported in rodents

    Theoretical
  • Aberrant dendritic branching at high doses in animals

    Theoretical
  • No peer-reviewed human safety trials exist; all safety data from rodents

    High
  • The 2014 Benoist et al. paper establishing the HGF/c-Met mechanism was retracted in 2025

    High
  • Unregulated products sold online; quality varies

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.